JP2022524449A5 - - Google Patents
Info
- Publication number
- JP2022524449A5 JP2022524449A5 JP2021554761A JP2021554761A JP2022524449A5 JP 2022524449 A5 JP2022524449 A5 JP 2022524449A5 JP 2021554761 A JP2021554761 A JP 2021554761A JP 2021554761 A JP2021554761 A JP 2021554761A JP 2022524449 A5 JP2022524449 A5 JP 2022524449A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antibody fragment
- region
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001775A JP7842914B2 (ja) | 2019-03-14 | 2025-01-06 | Ｃ５ａＲを標的とする抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19162759 | 2019-03-14 | ||
| EP19162759.5 | 2019-03-14 | ||
| PCT/EP2020/056754 WO2020182974A1 (en) | 2019-03-14 | 2020-03-13 | Antibodies targeting c5ar |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001775A Division JP7842914B2 (ja) | 2019-03-14 | 2025-01-06 | Ｃ５ａＲを標的とする抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524449A JP2022524449A (ja) | 2022-05-02 |
| JP2022524449A5 true JP2022524449A5 (enExample) | 2023-03-17 |
| JP7617012B2 JP7617012B2 (ja) | 2025-01-17 |
Family
ID=65812165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554761A Active JP7617012B2 (ja) | 2019-03-14 | 2020-03-13 | Ｃ５ａＲを標的とする抗体 |
| JP2025001775A Active JP7842914B2 (ja) | 2019-03-14 | 2025-01-06 | Ｃ５ａＲを標的とする抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001775A Active JP7842914B2 (ja) | 2019-03-14 | 2025-01-06 | Ｃ５ａＲを標的とする抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20220135658A1 (enExample) |
| EP (1) | EP3938393A1 (enExample) |
| JP (2) | JP7617012B2 (enExample) |
| KR (1) | KR102977518B1 (enExample) |
| CN (1) | CN113574072B (enExample) |
| AU (1) | AU2020235263B2 (enExample) |
| BR (1) | BR112021017860A2 (enExample) |
| CA (1) | CA3132771A1 (enExample) |
| IL (1) | IL286238A (enExample) |
| MA (1) | MA55285A (enExample) |
| MX (1) | MX2021011040A (enExample) |
| SG (1) | SG11202108761YA (enExample) |
| TW (1) | TWI901581B (enExample) |
| WO (1) | WO2020182974A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2022057910A1 (en) * | 2020-09-17 | 2022-03-24 | I-Mab Biopharma Co., Ltd | Combination therapies targeting c5ar and pd-1/pd-l1 pathways |
| US11912781B2 (en) * | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| WO2024236163A1 (en) | 2023-05-17 | 2024-11-21 | Morphosys Ag | T cell receptor beta constant region 2 (trbc2) antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
| CA2347973C (en) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| US8071096B2 (en) * | 2002-01-25 | 2011-12-06 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101559599B1 (ko) * | 2007-11-26 | 2015-10-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 항-메소텔린 항체 및 이의 용도 |
| CA2714296A1 (en) * | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| AU2011245117B2 (en) * | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| ES2929575T3 (es) * | 2011-06-06 | 2022-11-30 | Novo Nordisk As | Anticuerpos terapéuticos |
| DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| ES2736500T3 (es) | 2014-06-18 | 2020-01-02 | Morphosys Ag | Proteínas de fusión y usos de las mismas |
| AU2018286754A1 (en) * | 2017-06-23 | 2019-12-19 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
-
2020
- 2020-03-13 US US17/434,249 patent/US20220135658A1/en not_active Abandoned
- 2020-03-13 MX MX2021011040A patent/MX2021011040A/es unknown
- 2020-03-13 KR KR1020217032794A patent/KR102977518B1/ko active Active
- 2020-03-13 AU AU2020235263A patent/AU2020235263B2/en active Active
- 2020-03-13 BR BR112021017860A patent/BR112021017860A2/pt unknown
- 2020-03-13 SG SG11202108761YA patent/SG11202108761YA/en unknown
- 2020-03-13 EP EP20710933.1A patent/EP3938393A1/en active Pending
- 2020-03-13 MA MA055285A patent/MA55285A/fr unknown
- 2020-03-13 WO PCT/EP2020/056754 patent/WO2020182974A1/en not_active Ceased
- 2020-03-13 CN CN202080021131.1A patent/CN113574072B/zh active Active
- 2020-03-13 JP JP2021554761A patent/JP7617012B2/ja active Active
- 2020-03-13 TW TW109108367A patent/TWI901581B/zh active
- 2020-03-13 CA CA3132771A patent/CA3132771A1/en active Pending
-
2021
- 2021-09-09 IL IL286238A patent/IL286238A/en unknown
-
2023
- 2023-08-25 US US18/456,323 patent/US12018072B2/en active Active
-
2024
- 2024-05-08 US US18/658,860 patent/US20240400657A1/en active Pending
-
2025
- 2025-01-06 JP JP2025001775A patent/JP7842914B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191383A5 (enExample) | ||
| JP7583707B2 (ja) | 抗ｃｄ４７抗体及びその応用 | |
| JP2024109678A5 (enExample) | ||
| JP2022116269A5 (enExample) | ||
| JP2020108386A (ja) | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 | |
| JP2021526022A5 (enExample) | ||
| JP2021524244A5 (enExample) | ||
| CN115461368A (zh) | 抗人白细胞介素-4受体α抗体及其制备方法和应用 | |
| RU2014147773A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| JP2023545183A5 (enExample) | ||
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| JP2023093753A5 (enExample) | ||
| JP2020505927A5 (enExample) | ||
| JP2023545182A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| JP2024546763A5 (enExample) | ||
| JP2023506750A5 (enExample) | ||
| JP2023510844A5 (enExample) | ||
| JP2024546759A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| JP2026001077A5 (enExample) | ||
| JP2024516098A5 (enExample) | ||
| IL301276A (en) | Novel human antibodies that bind to human CD3-epsilon | |
| CN102690789A (zh) | 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用 |